Federal · U.S. Senate · Roll call 103April 23, 2026 · 02:51
On the Amendment S.Amdt. 5336 to S.Con.Res. 33 (No short title on file)
S.Con.Res. 33To establish a deficit-neutral reserve fund relating to requiring the Comptroller General of the United States to conduct a study related to economic consequences of private or confidential drug pricing agreements struck by any Federal department, agency, or office with any pharmaceutical manufacturer. 48–50Amendment Rejected (48-50)